NEWS HIGHLIGHTSMedia Articles Related to Recombivax HB (Hepatitis B Vaccine)
Flu Vaccination Rates Among Healthcare Workers Have Plateaued Source: Medscape Allergy & Clinical Immunology Headlines [2017.09.28] In addition, vaccination rates in the general US population were disappointingly low last year; they were highest in children aged 6 to 23 months, the CDC said. Medscape Medical News
Vaccination 101: Make Sure Kids Are Up to Date Source: MedicineNet Encephalitis and Meningitis Specialty [2017.08.28] Title: Vaccination 101: Make Sure Kids Are Up to Date Category: Health News Created: 8/28/2017 12:00:00 AM Last Editorial Review: 8/28/2017 12:00:00 AM
Vaccination Schedule for Adults and Adolescents Source: MedicineNet Tuberculosis Skin Test (PPD Skin Test) Specialty [2016.09.14] Title: Vaccination Schedule for Adults and Adolescents Category: Procedures and Tests Created: 12/31/1997 12:00:00 AM Last Editorial Review: 9/14/2016 12:00:00 AM
Published Studies Related to Recombivax HB (Hepatitis B Vaccine)
Long-term efficacy of a hepatitis E vaccine. [2015] long-term efficacy of a hepatitis E vaccine needs to be determined... CONCLUSIONS: Immunization with this hepatitis E vaccine induced antibodies
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. [2011.07] BACKGROUND: A modified process hepatitis B vaccine (mpHBV) uses higher phosphate content in the manufacturing process relative to the current product, Recombivax-HB. The higher phosphate is thought to improve antigen presentation, and thereby, increase antibody production. The mpHBV was previously shown to be well tolerated and immunogenic in adults. The current study tested a 2-, 4-, 6-month vaccination schedule and a higher dose formulation (10 mug mpHBV) in healthy infants... CONCLUSIONS: All 4 hepatitis B vaccines elicited high anti-HBs SPRs. After dose 3, anti-HBs GMT were highest in the 10 mug mpHBV group, but did not meet the predefined criteria for superiority. All vaccines were well tolerated.
Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. [2011.06] BACKGROUND AND AIMS: Assessment of a new, fully liquid, investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi Pasteur), containing the same active ingredients as Pentaxim (DTaP-IPV//PRT-T) and 10 mug Hansenula polymorpha-derived recombinant hepatitis B (Hep B) surface antigen, Sanofi Pasteur, in Argentinean infants... CONCLUSIONS: The new, fully liquid, investigational DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) is highly immunogenic and safe when compared with licensed comparators, warranting further development.
Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients. [2011.05] OBJECTIVES: The aim of the study was to evaluate the effect of high-flux (HF) hemodialysis (HD) on delayed protective hepatitis B virus (HBV) antibody seroconversion in HD patients who had no response to the classic third dose of HBV vaccination... CONCLUSION: Hemodialysis patients who do not respond to the classic third dose of HBV vaccination could reobtain a delayed higher protective HBV antibody seroconversion rate by HF HD without other intervention.
Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination. [2011.05] BACKGROUND: Prisoners and injecting drug users are at constant risk of hepatitis B virus (HBV) infection and the classic 6-months HBV vaccination might not provide immunization rapidly enough. In this randomized clinical trial we investigated the efficacy of an accelerated vaccination protocol vs. classic schedule among prisoners in Iran... CONCLUSION: Compared to classic HBV vaccination regimen, an accelerated 0, 1, 4 and 8 weeks vaccination schedule can achieve early seroprotection more rapidly, provides clinically sufficient seroprotection with higher compliance in prisoners and can be suggested in situations that rapid immunization against HBV infection is warranted. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Clinical Trials Related to Recombivax HB (Hepatitis B Vaccine)
The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines [Completed]
This study is an expanded Phase 2/Phase 3 clinical trial base on the safety data obtained
from the phase 1 clinical trial. The purpose of this study is to further evaluate the
immunogenicity and safety of 60mcg/30mcg recombinant hepatitis B vaccines in people aged 16
and older who failed to respond to routine administration of 10mcg recombinant hepatitis B
vaccines and to explore the optimizing immunizing dose and immune procedure.
Study of Evaluating Safety and Immunogenicity of 10�g/0.5ml Hepatitis B Vaccine [Completed]
The main objective of this study was to evaluate the safety and immunogenicity of 10µg/0. 5ml
and 5µg/0. 5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in
saccharomyces cereviside yeast for infants and other age groups.
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060) [Completed]
Hepatitis B Vaccine Booster Study (V232-058) [Completed]
To assess the safety and immunogenicity of a booster dose of hepatitis B vaccine in children
who have received a 3-dose primary series of either RECOMBIVAX HB or ENGERIX-B. The primary
vaccination series (was given 4 to 8 years prior to study entry and consisted of a licensed
hepatitis B vaccine product (either RECOMBIVAX HB or ENGERIX-B). The booster dose given in
this study will be either an investigational Merck product (Modified Process Hepatitis B
Vaccine) or licensed ENGERIX-B vaccine.
A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) [Completed]
A study to evaluate the safety, tolerability, and immunogenicity of a recombinant hepatitis
B vaccine manufactured using an upgrade to the production process. The primary hypotheses
tested at 1 month after the third dose of vaccine are the following: 1) the 3 lots of the
process upgrade vaccine induce similar seroprotection rates to hepatitis B surface antigen
(HBsAg), 2) the combined lots of the process upgrade vaccine induce adequate seroprotection
to HBsAg, and 3) the process upgrade vaccine will induce geometric mean antibody titers to
HBsAg that are non-inferior or superior to those induced by the current process vaccine.
|